Portal de investigación
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Daver, Naval G.
- DeAngelo, Daniel J.
- Wang, Eunice S.
- Papadantonakis, Nikolaos
- Deconinck, Eric
- Erba, Harry P.
- Pemmaraju, Naveen
- Lane, Andrew A.
- Rizzieri, David A.
- Sweet, Kendra L.
- Martinelli, Giovanni
- Tarella, Corrado
- Todisco, Elisabetta
- Konopleva, Marina Y.
- Sloss, Callum M.
- Culm-Merdek, Kerry
- Zweidler-McKay, Patrick A.
- Kantarjian, Hagop M.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 5,416 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Blood AMER SOC HEMATOLOGY
Citas Recibidas en Web of Science: 26
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Daver,NG,Montesinos,P,DeAngelo,DJ,Wang,ES,Papadantonakis,N,Deconinck,E,Erba,HP et al. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2019. Orlando-FL. 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA:AMER SOC HEMATOLOGY. 2019.